- Non-Steroidal Anti Inflammatory Drugs (NSAIDs)
- TNF Alfa Inhibitors
- Corticosteroids
- Interleukin Inhibitors
- PDE4 Inhibitors
- Others
Psoriatic Arthritis Treatment Market size was valued at USD 7.61 billion in 2022 and is poised to grow at a CAGR of 9.5% from 2023-2029. Psoriatic Arthritis is a form of arthritis developed in people affected by psoriasis. It causes affected joints to become swollen, stiff, and painful. Most of the people affected by psoriasis are first and later diagnosed with psoriatic arthritis. Approximately 15-25% of people with psoriasis can develop psoriatic arthritis. Symptoms associated with psoriatic arthritis include swollen joints, low back pain, nail pitting, conjunctivitis, and foot pain among others. Psoriatic arthritis is a type of arthritis that affects some people who suffer from psoriasis, a dyskinesia ailment that causes red patches with silvery scales. The majority of people first acquire psoriasis before being diagnosed with psoriatic arthritis. Joint difficulties, on the other hand, might occasionally start before skin patches emerge. When the immune system attacks healthy cells and tissue, this disease develops. Inflammation of the joints, as well as an overproduction of skin cells, are caused by an aberrant immunological response.
Global Psoriatic Arthritis Psa Treatments Market Summary
Study Period
2024-2030Base Year
2023CAGR
9.5%Largest Market
EuropeFastest Growing Market
North-AmericaPsoriatic Arthritis Treatment Market Dynamics
Increase in the prevalence of psoriasis results to rise in number of psoriatic arthritis patients is a key factor enhance the revenue of psoriatic arthritis market. Moreover, rise in R&D for the innovation of newer products, pipeline drugs under various stages of clinical trials, frequent product launchings by the market players, and increase in the awareness about psoriatic arthritis treatment among the healthcare professionals are expected to drive the global psoriatic treatment market over the forecast years. However, stringent regulations for the product approval, high cost of treatment, entry of biosimilars into market, and lack of standardization tools for diagnosis and treatment are restrain the growth of the market.
North-America got significant share
Psoriatic Arthritis Treatment Market Regional Analysis
Geographically, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America psoriatic arthritis treatment market is poised to grow due to rise in R&D for the innovation of newer drugs, increase in the prevalence of psoriatic arthritis in U.S., and grow in healthcare expenditure are bolster the market. Europe psoriatic arthritis treatment market is driving by rise in adoption of newer therapeutics, increase in government funding for healthcare sector, and promising pipeline products are surge the market. Asia Pacific psoriatic arthritis treatment market has prominent share attributed to large patient pool in India and China, launching of newer products in Asia Pacific region, and development in healthcare infrastructure are boost the market over the forecast years.
Latin America
Europe
Asia Pacific
Middle East
North America
Global Psoriatic Arthritis Psa Treatments Market Segmentation
By Drug Class
By Disease Condition
- Mild
- Moderate
- Severe
By Route Administration
- Oral
- Parenteral
- Topical
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Frequently Asked Questions
The key segments covered in the psoriatic arthritis treatment market are: by drug class, disease indication, route of administration, distribution channel and geography
The psoriatic arthritis treatment market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
The psoriatic arthritis treatment market key players are: Bristol Myers Squibb Company (U.S.), Hoffmann La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Amgen, Inc. (U.S.), Hohnson & Johnson Services, Inc. (U.S.)
Key Features of the Report
- The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
- The report covers in-detail insights about the competitors overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startups details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porters Five Force Analysis in addition to recent technology advancements and innovations in the market
| 1. Executive Summary |
| 2. Global Psoriatic Arthritis Psa Treatments Market Introduction |
| 2.1.Global Psoriatic Arthritis Psa Treatments Market - Taxonomy |
| 2.2.Global Psoriatic Arthritis Psa Treatments Market - Definitions |
| 2.2.1.Drug Class |
| 2.2.2.Disease Condition |
| 2.2.3.Route Administration |
| 2.2.4.Distribution Channel |
| 2.2.5.Region |
| 3. Global Psoriatic Arthritis Psa Treatments Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Psoriatic Arthritis Psa Treatments Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Psoriatic Arthritis Psa Treatments Market By Drug Class, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 5.1. Non-Steroidal Anti Inflammatory Drugs (NSAIDs) |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. TNF Alfa Inhibitors |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Corticosteroids |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Interleukin Inhibitors |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. PDE4 Inhibitors |
| 5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Others |
| 5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 6. Global Psoriatic Arthritis Psa Treatments Market By Disease Condition, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 6.1. Mild |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Moderate |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Severe |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Global Psoriatic Arthritis Psa Treatments Market By Route Administration, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 7.1. Oral |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Parenteral |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Topical |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 8. Global Psoriatic Arthritis Psa Treatments Market By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 8.1. Hospital Pharmacies |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Retail Pharmacies |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Online Pharmacies |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 9. Global Psoriatic Arthritis Psa Treatments Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10. North America Psoriatic Arthritis Psa Treatments Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 10.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Non-Steroidal Anti Inflammatory Drugs (NSAIDs) |
| 10.1.2.TNF Alfa Inhibitors |
| 10.1.3.Corticosteroids |
| 10.1.4.Interleukin Inhibitors |
| 10.1.5.PDE4 Inhibitors |
| 10.1.6.Others |
| 10.2. Disease Condition Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Mild |
| 10.2.2.Moderate |
| 10.2.3.Severe |
| 10.3. Route Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Oral |
| 10.3.2.Parenteral |
| 10.3.3.Topical |
| 10.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Hospital Pharmacies |
| 10.4.2.Retail Pharmacies |
| 10.4.3.Online Pharmacies |
| 10.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11. Europe Psoriatic Arthritis Psa Treatments Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 11.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Non-Steroidal Anti Inflammatory Drugs (NSAIDs) |
| 11.1.2.TNF Alfa Inhibitors |
| 11.1.3.Corticosteroids |
| 11.1.4.Interleukin Inhibitors |
| 11.1.5.PDE4 Inhibitors |
| 11.1.6.Others |
| 11.2. Disease Condition Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Mild |
| 11.2.2.Moderate |
| 11.2.3.Severe |
| 11.3. Route Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Oral |
| 11.3.2.Parenteral |
| 11.3.3.Topical |
| 11.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Hospital Pharmacies |
| 11.4.2.Retail Pharmacies |
| 11.4.3.Online Pharmacies |
| 11.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 11.5.6.Rest of EU |
| 12. Asia Pacific (APAC) Psoriatic Arthritis Psa Treatments Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 12.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Non-Steroidal Anti Inflammatory Drugs (NSAIDs) |
| 12.1.2.TNF Alfa Inhibitors |
| 12.1.3.Corticosteroids |
| 12.1.4.Interleukin Inhibitors |
| 12.1.5.PDE4 Inhibitors |
| 12.1.6.Others |
| 12.2. Disease Condition Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Mild |
| 12.2.2.Moderate |
| 12.2.3.Severe |
| 12.3. Route Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Oral |
| 12.3.2.Parenteral |
| 12.3.3.Topical |
| 12.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Hospital Pharmacies |
| 12.4.2.Retail Pharmacies |
| 12.4.3.Online Pharmacies |
| 12.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13. Middle East and Africa (MEA) Psoriatic Arthritis Psa Treatments Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 13.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Non-Steroidal Anti Inflammatory Drugs (NSAIDs) |
| 13.1.2.TNF Alfa Inhibitors |
| 13.1.3.Corticosteroids |
| 13.1.4.Interleukin Inhibitors |
| 13.1.5.PDE4 Inhibitors |
| 13.1.6.Others |
| 13.2. Disease Condition Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Mild |
| 13.2.2.Moderate |
| 13.2.3.Severe |
| 13.3. Route Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Oral |
| 13.3.2.Parenteral |
| 13.3.3.Topical |
| 13.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Hospital Pharmacies |
| 13.4.2.Retail Pharmacies |
| 13.4.3.Online Pharmacies |
| 13.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14. Latin America Psoriatic Arthritis Psa Treatments Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 14.1. Drug Class Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Non-Steroidal Anti Inflammatory Drugs (NSAIDs) |
| 14.1.2.TNF Alfa Inhibitors |
| 14.1.3.Corticosteroids |
| 14.1.4.Interleukin Inhibitors |
| 14.1.5.PDE4 Inhibitors |
| 14.1.6.Others |
| 14.2. Disease Condition Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Mild |
| 14.2.2.Moderate |
| 14.2.3.Severe |
| 14.3. Route Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.Oral |
| 14.3.2.Parenteral |
| 14.3.3.Topical |
| 14.4. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Hospital Pharmacies |
| 14.4.2.Retail Pharmacies |
| 14.4.3.Online Pharmacies |
| 14.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1.Bristol-Myers Squibb Company (U.S.) |
| 15.2.2.Hoffmann La Roche Ltd. (Switzerland) |
| 15.2.3.Novartis AG (Switzerland) |
| 15.2.4.Amgen, Inc. (U.S.) |
| 15.2.5.Hohnson & Johnson Services, Inc. (U.S.) |
| 15.2.6.AbbVie Inc. (U.S.) |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
- Bristol-Myers Squibb Company (U.S.)
- Hoffmann La Roche Ltd. (Switzerland)
- Novartis AG (Switzerland)
- Amgen, Inc. (U.S.)
- Hohnson & Johnson Services, Inc. (U.S.)
- AbbVie Inc. (U.S.)
- Eli Lilly & Co. (U.S.)
- UCB Inc. (Belgium)
- Celgene Corporation (U.S.)
- Valeant Pharmaceuticals International, Inc. (U.S.)